CN101410189A - 用以施用药物制剂的剂量喷雾器 - Google Patents
用以施用药物制剂的剂量喷雾器 Download PDFInfo
- Publication number
- CN101410189A CN101410189A CNA200780011089XA CN200780011089A CN101410189A CN 101410189 A CN101410189 A CN 101410189A CN A200780011089X A CNA200780011089X A CN A200780011089XA CN 200780011089 A CN200780011089 A CN 200780011089A CN 101410189 A CN101410189 A CN 101410189A
- Authority
- CN
- China
- Prior art keywords
- amino
- phenyl
- quinazoline
- chloro
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 11
- 239000000443 aerosol Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 claims abstract description 11
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims abstract description 4
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000007921 spray Substances 0.000 claims description 18
- 239000011149 active material Substances 0.000 claims description 16
- 239000005557 antagonist Substances 0.000 claims description 9
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 8
- 229940121647 egfr inhibitor Drugs 0.000 claims description 8
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 claims description 6
- 239000000812 cholinergic antagonist Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 229940127597 CGRP antagonist Drugs 0.000 claims description 2
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 claims description 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000003380 propellant Substances 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract 6
- 238000009472 formulation Methods 0.000 abstract 2
- -1 EGFR-inhibitor Substances 0.000 description 135
- 239000002585 base Substances 0.000 description 107
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 97
- 229910052760 oxygen Inorganic materials 0.000 description 67
- 239000001301 oxygen Substances 0.000 description 67
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 39
- 150000003839 salts Chemical class 0.000 description 32
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 18
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 230000001078 anti-cholinergic effect Effects 0.000 description 14
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 12
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 12
- 229910019142 PO4 Inorganic materials 0.000 description 12
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 12
- 239000010452 phosphate Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 10
- 239000012453 solvate Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229940095064 tartrate Drugs 0.000 description 8
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 7
- 229960003210 hyoscyamine Drugs 0.000 description 7
- 229930005342 hyoscyamine Natural products 0.000 description 7
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 7
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 229910002651 NO3 Inorganic materials 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 150000003891 oxalate salts Chemical class 0.000 description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 6
- 229950004288 tosilate Drugs 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- 150000003842 bromide salts Chemical group 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229940006460 bromide ion Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- PZDAAZQDQJGXSW-UHFFFAOYSA-N 1-fluoro-4-(4-fluorophenyl)benzene Chemical group C1=CC(F)=CC=C1C1=CC=C(F)C=C1 PZDAAZQDQJGXSW-UHFFFAOYSA-N 0.000 description 3
- 241000370738 Chlorion Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 3
- 229940006461 iodide ion Drugs 0.000 description 3
- UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 description 3
- 229960003019 loprazolam Drugs 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000003186 pharmaceutical solution Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- ULMFXAMQUGLVGA-LJQANCHMSA-N 3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-n-[(2r)-4,4,4-trifluoro-2-methylbutyl]indole-5-carboxamide Chemical compound C=1C=C(CC=2C3=CC(=CC=C3N(C)C=2)C(=O)NC[C@H](C)CC(F)(F)F)C(OC)=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C ULMFXAMQUGLVGA-LJQANCHMSA-N 0.000 description 2
- CVDXFPBVOIERBH-JWQCQUIFSA-N 4-[(4ar,10bs)-9-ethoxy-8-methoxy-2-methyl-3,4,4a,10b-tetrahydro-1h-benzo[c][1,6]naphthyridin-6-yl]-n,n-di(propan-2-yl)benzamide Chemical compound N([C@@H]1CCN(C)C[C@@H]1C=1C=C(C(=CC=11)OC)OCC)=C1C1=CC=C(C(=O)N(C(C)C)C(C)C)C=C1 CVDXFPBVOIERBH-JWQCQUIFSA-N 0.000 description 2
- PYUGFOWNYMLROI-KPKJPENVSA-N 8-[(e)-2-[4-[4-(4-fluorophenyl)butoxy]phenyl]ethenyl]-2-(2h-tetrazol-5-yl)chromen-4-one Chemical compound C1=CC(F)=CC=C1CCCCOC(C=C1)=CC=C1\C=C\C1=CC=CC2=C1OC(C=1NN=NN=1)=CC2=O PYUGFOWNYMLROI-KPKJPENVSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- DHCOPPHTVOXDKU-UHFFFAOYSA-N Tofimilast Chemical compound C1CN2C(C=3SC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 DHCOPPHTVOXDKU-UHFFFAOYSA-N 0.000 description 2
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 description 2
- HOAKOHHSHOCDLI-TUFAYURCSA-N [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-sulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CS)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O HOAKOHHSHOCDLI-TUFAYURCSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
- 229950001167 butixocort Drugs 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 2
- 229960001145 deflazacort Drugs 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002168 ethanoic acid esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960002848 formoterol Drugs 0.000 description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 2
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 description 2
- 229960001798 loteprednol Drugs 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 2
- HHRNQOGXBRYCHF-UHFFFAOYSA-N n-[2-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide Chemical compound CC(C)NCC(O)C1=CC=C(O)C(NS(C)(=O)=O)=C1 HHRNQOGXBRYCHF-UHFFFAOYSA-N 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229950010289 soterenol Drugs 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 2
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 2
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XJBCFFLVLOPYBV-UHFFFAOYSA-N zinterol Chemical compound C=1C=C(O)C(NS(C)(=O)=O)=CC=1C(O)CNC(C)(C)CC1=CC=CC=C1 XJBCFFLVLOPYBV-UHFFFAOYSA-N 0.000 description 2
- 229950004209 zinterol Drugs 0.000 description 2
- XJSMBWUHHJFJFV-VTIMJTGVSA-N α-dihydroergocryptine Chemical compound C([C@H]1N(C)C2)C([C]34)=CN=C4C=CC=C3[C@H]1C[C@H]2C(=O)N[C@@]1(C(C)C)C(=O)N2[C@@H](CC(C)C)C(=O)N3CCC[C@H]3[C@]2(O)O1 XJSMBWUHHJFJFV-VTIMJTGVSA-N 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- YVAIFZYQODGYQY-UHFFFAOYSA-N 2,3-dihydro-1,3-benzothiazole 1-oxide Chemical class C1=CC=C2S(=O)CNC2=C1 YVAIFZYQODGYQY-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
- MAGCRYYXZYUDSY-UHFFFAOYSA-N 2-fluoro-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(F)(C(=O)O)C1=CC=CC=C1 MAGCRYYXZYUDSY-UHFFFAOYSA-N 0.000 description 1
- XBUSQTCUZRYVMT-UHFFFAOYSA-N 2-hydroxy-5-[1-hydroxy-2-[2-[4-[(2-hydroxy-2-phenylethyl)amino]phenyl]ethylamino]ethyl]benzaldehyde Chemical compound C=1C=C(O)C(C=O)=CC=1C(O)CNCCC(C=C1)=CC=C1NCC(O)C1=CC=CC=C1 XBUSQTCUZRYVMT-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
- NMGODFWGUBLTTA-UHFFFAOYSA-N 3-amino-1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)N(N)C(=O)NC2=C1 NMGODFWGUBLTTA-UHFFFAOYSA-N 0.000 description 1
- PLHHWRFVKOIFNG-UHFFFAOYSA-N 4-(5,5-dimethyl-2-oxomorpholin-4-yl)-n-[4-(3-ethynylanilino)quinazolin-6-yl]but-2-enamide Chemical compound CC1(C)COC(=O)CN1CC=CC(=O)NC1=CC=C(N=CN=C2NC=3C=C(C=CC=3)C#C)C2=C1 PLHHWRFVKOIFNG-UHFFFAOYSA-N 0.000 description 1
- LIXBJWRFCNRAPA-NSHDSACASA-N 4-[(1r)-2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C=C1Cl LIXBJWRFCNRAPA-NSHDSACASA-N 0.000 description 1
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 description 1
- LIXBJWRFCNRAPA-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C=C1Cl LIXBJWRFCNRAPA-UHFFFAOYSA-N 0.000 description 1
- MNJNSRQVLNIPFN-UHFFFAOYSA-N 4-[2-[[4-(benzimidazol-1-yl)-2-methylbutan-2-yl]amino]-1-hydroxyethyl]-2-[(4-methoxyphenyl)methylamino]phenol Chemical compound C1=CC(OC)=CC=C1CNC1=CC(C(O)CNC(C)(C)CCN2C3=CC=CC=C3N=C2)=CC=C1O MNJNSRQVLNIPFN-UHFFFAOYSA-N 0.000 description 1
- KOTMQCNDGLTIHR-UHFFFAOYSA-N 4-[2-[[4-(benzimidazol-1-yl)-2-methylbutan-2-yl]amino]-1-hydroxyethyl]-3-fluorophenol Chemical compound C1=NC2=CC=CC=C2N1CCC(C)(C)NCC(O)C1=CC=C(O)C=C1F KOTMQCNDGLTIHR-UHFFFAOYSA-N 0.000 description 1
- XRYJULCDUUATMC-CYBMUJFWSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 XRYJULCDUUATMC-CYBMUJFWSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
- NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 1
- ZRDOWGBNGIHJTG-UHFFFAOYSA-N 9-(hydroxymethyl)xanthene-9-carboxylic acid Chemical compound C1=CC=C2C(CO)(C(O)=O)C3=CC=CC=C3OC2=C1 ZRDOWGBNGIHJTG-UHFFFAOYSA-N 0.000 description 1
- DTZDZCNXNYMMOW-UHFFFAOYSA-N 9-hydroxyxanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)(O)C3=CC=CC=C3OC2=C1 DTZDZCNXNYMMOW-UHFFFAOYSA-N 0.000 description 1
- CBNOKZSYCBHRAD-UHFFFAOYSA-N 9-methylxanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C)(C(O)=O)C3=CC=CC=C3OC2=C1 CBNOKZSYCBHRAD-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- QGBIFMJAQARMNQ-QISPFCDLSA-N C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O QGBIFMJAQARMNQ-QISPFCDLSA-N 0.000 description 1
- PFBDPDKTTUYHPU-RUZDIDTESA-N CO[C@H]1CN(CC(=O)O1)CC=CC(=O)NC2=C(C=C3C(=C2)C(=NC(=N3)OC)NC4=CC(=C(C=C4)F)Cl)C5CC5 Chemical compound CO[C@H]1CN(CC(=O)O1)CC=CC(=O)NC2=C(C=C3C(=C2)C(=NC(=N3)OC)NC4=CC(=C(C=C4)F)Cl)C5CC5 PFBDPDKTTUYHPU-RUZDIDTESA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- YUPJAGURWFHXGG-UHFFFAOYSA-N N-[4-(3-chloro-4-fluoroanilino)-7-cyclopropyl-2-methoxyquinazolin-6-yl]-4-(diethylamino)but-2-enamide Chemical compound ClC=1C=C(C=CC=1F)NC1=NC(=NC2=CC(=C(C=C12)NC(C=CCN(CC)CC)=O)C1CC1)OC YUPJAGURWFHXGG-UHFFFAOYSA-N 0.000 description 1
- PMCUMLQRHVKPMA-OAHLLOKOSA-N N-[4-(3-chloro-4-fluoroanilino)-7-cyclopropyl-2-methoxyquinazolin-6-yl]-4-[(2R)-2-methyl-6-oxomorpholin-4-yl]but-2-enamide Chemical compound ClC=1C=C(C=CC=1F)NC1=NC(=NC2=CC(=C(C=C12)NC(C=CCN1CC(O[C@@H](C1)C)=O)=O)C1CC1)OC PMCUMLQRHVKPMA-OAHLLOKOSA-N 0.000 description 1
- LSAVAUSXBDYARZ-UHFFFAOYSA-N N-[4-(3-chloro-4-fluoroanilino)-7-cyclopropyl-2-methoxyquinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound ClC=1C=C(C=CC=1F)NC1=NC(=NC2=CC(=C(C=C12)NC(C=CCN1CCOCC1)=O)C1CC1)OC LSAVAUSXBDYARZ-UHFFFAOYSA-N 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- RUOGJYKOQBFJIG-UHFFFAOYSA-N SCH-351591 Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)NC1=C(Cl)C=[N+]([O-])C=C1Cl RUOGJYKOQBFJIG-UHFFFAOYSA-N 0.000 description 1
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- YPFLFUJKZDAXRA-UHFFFAOYSA-N [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate Chemical compound O1C2=CC(OS(=O)(=O)C)=CC=C2C(NC(N)=O)=C1C(=O)C1=CC=C(Cl)C=C1Cl YPFLFUJKZDAXRA-UHFFFAOYSA-N 0.000 description 1
- WKHOPHIMYDJVSA-UHFFFAOYSA-N [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate Chemical compound CC(C)C(=O)OC1=CC(OC(=O)C(C)C)=CC(C(O)CNC(C)(C)C)=C1 WKHOPHIMYDJVSA-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960001692 arformoterol Drugs 0.000 description 1
- GVTLDPJNRVMCAL-UHFFFAOYSA-N arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 description 1
- 229950009746 arofylline Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229960002526 bamipine Drugs 0.000 description 1
- VZSXTYKGYWISGQ-UHFFFAOYSA-N bamipine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CC=C1 VZSXTYKGYWISGQ-UHFFFAOYSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000003454 betamimetic effect Effects 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- JBRBWHCVRGURBA-UHFFFAOYSA-N broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 description 1
- 229950008847 broxaterol Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- 150000003841 chloride salts Chemical group 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960003686 chlorphenoxamine Drugs 0.000 description 1
- KKHPNPMTPORSQE-UHFFFAOYSA-N chlorphenoxamine Chemical compound C=1C=C(Cl)C=CC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KKHPNPMTPORSQE-UHFFFAOYSA-N 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical group C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229960001992 dimetindene Drugs 0.000 description 1
- MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical compound CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- 229940099182 dramamine Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- 229960000325 emedastine Drugs 0.000 description 1
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 1
- QVDKSPUZWYTNQA-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=NC=N[C]21 QVDKSPUZWYTNQA-UHFFFAOYSA-N 0.000 description 1
- 229950000579 enprofylline Drugs 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- JTXYEERBIZXLJC-DCJXKKNWSA-N ethyl (8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-17-carboxylate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCC)(O)[C@@]1(C)C[C@@H]2O JTXYEERBIZXLJC-DCJXKKNWSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- OATDVDIMNNZTEY-DAXLTYESSA-N flutropium Chemical class C[N@@+]1(CCF)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1 OATDVDIMNNZTEY-DAXLTYESSA-N 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 229960000708 hexoprenaline Drugs 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- TWTMQRXNAZGSCE-UHFFFAOYSA-N hydron;[6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;chloride Chemical compound Cl.C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 TWTMQRXNAZGSCE-UHFFFAOYSA-N 0.000 description 1
- 229950002451 ibuterol Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229960001120 levocabastine Drugs 0.000 description 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 229950008462 lirimilast Drugs 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229950001737 meluadrine Drugs 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- NPGREARFJMFTDF-UHFFFAOYSA-N n-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)N=C1C(Cl)=CN(O)C=C1Cl NPGREARFJMFTDF-UHFFFAOYSA-N 0.000 description 1
- BMKINZUHKYLSKI-UHFFFAOYSA-N n-[2-hydroxy-5-[1-hydroxy-2-[2-[4-[(2-hydroxy-2-phenylethyl)amino]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C=1C=C(O)C(NC=O)=CC=1C(O)CNCCC(C=C1)=CC=C1NCC(O)C1=CC=CC=C1 BMKINZUHKYLSKI-UHFFFAOYSA-N 0.000 description 1
- GWFMAFOGZMQEDM-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N1=CN=C2C=C(OC3CCCC3)C(NC(=O)C=CCN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 GWFMAFOGZMQEDM-UHFFFAOYSA-N 0.000 description 1
- UBUIJVSWEKUFRP-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]-4-[cyclopropyl(methyl)amino]but-2-enamide Chemical compound C1CC1N(C)CC=CC(=O)NC(C(=CC1=NC=N2)OC3CCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 UBUIJVSWEKUFRP-UHFFFAOYSA-N 0.000 description 1
- ADOYXBQVLRRQGX-OAQYLSRUSA-N n-[7-cyclopentyloxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C1=CC=2NC(=O)C=CCN3CCOCC3)=NC=NC1=CC=2OC1CCCC1 ADOYXBQVLRRQGX-OAQYLSRUSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical class CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YYPWGCZOLGTTER-MZMPZRCHSA-N pergolide Chemical compound C1=CC=C2[C@H]3C[C@@H](CSC)CN(CCC)[C@@H]3CC3=CN=C1[C]32 YYPWGCZOLGTTER-MZMPZRCHSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 229950010090 pumafentrine Drugs 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229950000366 roxindole Drugs 0.000 description 1
- BKTTWZADZNUOBW-UHFFFAOYSA-N roxindole Chemical compound C=12[CH]C(O)=CC=C2N=CC=1CCCCN(CC=1)CCC=1C1=CC=CC=C1 BKTTWZADZNUOBW-UHFFFAOYSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229950001879 salmefamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229950008418 talipexole Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960004558 terguride Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
- 229950010302 tiaramide Drugs 0.000 description 1
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 229950003899 tofimilast Drugs 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/06—Gas or vapour producing the flow, e.g. from a compressible bulb or air pump
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
- B65D83/75—Aerosol containers not provided for in groups B65D83/16 - B65D83/74
- B65D83/753—Aerosol containers not provided for in groups B65D83/16 - B65D83/74 characterised by details or accessories associated with outlets
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/30—Materials not provided for elsewhere for aerosols
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Mechanical Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Abstract
本发明涉及在含推进剂的[1.1.1.2-四氟乙烷(HFC-134a)或1.1.1.2.3.3.3-七氟丙烷(HFC-227)]计量剂量喷雾剂中作为喷雾剂的药用活性物质、活性物质混合物以及制剂,且涉及用于给药这些活性物质、活性物质混合物及制剂的计量剂量喷雾器。
Description
本发明涉及在含推进剂[1.1.1.2-四氟乙烷(HFC-134a)或1.1.1.2.3.3.3-七氟丙烷(HFC-227)]计量剂量喷雾剂中作为喷雾剂的药用活性物质、活性物质混合物以及制剂,以及用于给药这些活性物质、活性物质混合物及制剂的计量剂量喷雾器。
先前技术
在治疗中(例如,在哮喘及导致气道阻塞的疾病的治疗中)广泛地使用通过加压、剂量量测吸入器(MDI,代表“计量剂量吸入器”)递送医药的喷雾剂制剂。与口服相比,吸入使得活性更快生效且同时将全身副作用减至最小。可通过经口腔吸入或局部地通过施加于鼻粘膜给药喷雾剂制剂。
用于使用MDI给药喷雾剂的制剂可由溶液或悬浮液组成。溶液制剂具有优于悬浮液制剂的优点,此乃因医药组合物完全地溶解于推进剂内且因而具有均相性质。溶液制剂亦避免了与悬浮液制剂的物理不稳定性相关联的问题,且因而保证长时期等剂量给药。另外,溶液型计量剂量喷雾剂一般不需要添加表面活性剂。此外,如(例如)美国专利第2004/0184994号中所公开,存在所谓“悬浊液(suslutions)”。
喷雾剂溶液制剂通过MDI的给药取决于用于产生喷雾剂的推进系统的推进力。
通常,该推进剂含有氯氟碳化合物(CFC)的混合物以保证该制剂的溶解度、蒸气压及稳定性的合意特性。然而,如已经确定CFC同时破坏环境,此乃因消耗地球臭氧层,故正在用环境可接受的部分氟化的烃推进剂(HFC推进剂)或其他未被氯化的推进剂替代喷雾剂吸入制剂中存在的环境有害CFC推进剂。
尽管市场中存在诸多计量剂量喷雾剂,但其计量精确度仍有待改。
本发明的目的是提供一种对于所制备的活性物质、活性物质混合物或制剂具有增加的计量精确度的装置。
上述目的是通过根据权利要求1的装置事先。其他有利特征是附属权利要求的客体。
在本发明的第一方面中,该装置的吸嘴管具有通道8,该通道于其远离该计量剂量喷雾剂的一侧上没有或几乎没有死区(dead volume)。
术语“死区”定义为突出于喷嘴孔9之外的并因而不处在直接的流动路径之内的空间。
附图简述
根据下文阐述的优选实施方案并参照这些附图,本发明的其他优点、特征、特性及方面将变得显而易见,其中:
图1:显示具有死区的吸嘴管;
图2:显示具有减少死区的吸嘴管;
图3及4:显示具有最佳减少死区的吸嘴管(在所有情形中皆为根据本发明的吸嘴)。
图5:显示如图1a中一样但具有参考数字的吸嘴管。
在所有情形中,标注“a”的图式显示侧视图中的纵剖面。
在所有情形中,标注“b”的图式显示平面图中的纵剖面。
在这些图式中,相同编号用于具有对应或相当特性及优点的相同或类似部件,即使未重复对应说明。
该吸嘴管是具有数个功能的组件:
根据图5的吸嘴管在功能上是由竖筒2、阀杆插座5、喷嘴孔9及吸嘴6构成。
该吸嘴管这样容纳该计量剂量喷雾剂,即,使该吸嘴管的竖筒2环绕计量剂量喷雾剂1,并且该吸嘴管的阀杆插座5密闭地环抱计量阀门3的阀杆4。
吸嘴管竖筒2具有通过限制该计量剂量喷雾剂移动的空间来安全地防止阀杆4相对于其他阀门组件3的倾斜(此倾斜将对阀门3有害)的功能。另外,该阀杆插座5形成拱台,其限制该阀杆4在该吸嘴管的杆插座内的浸入深度。
该阀杆插座具有通道8,其中,该实际喷嘴孔9相对于该通道的垂直轴线呈钝夹角地通向该通道。如用于悬浮液制剂及悬浊液,该喷嘴孔具有0.2-0.6mm的直径,优选介于0.5-0.6mm之间,并且,如用于溶液制剂,该喷嘴孔具有介于0.2-0.27mm之间的直径。
因此,在压力下液化的活性物质制剂可自阀杆7的垂直向下配置的开口偏转>90°并且经由喷嘴孔9通向外部。喷雾云最终是在自喷嘴孔9至喷嘴开口10的过渡处产生。
通过常规的注塑方法来实质上更精确地定位工具部件(包括喷嘴针及该阀杆插座的核心相对于彼此的定位),以达成本发明所描述吸嘴管的变化。
阀杆尺寸的实例:
阀门/制造商 | 阀杆外径 | 阀杆开口处的内径 |
Bespak,BK357 | 3.17±0.01mm | 2.12±0.03mm |
Valois,DF31/50RCU | 3.19±0.01mm | 1.48±0.02mm |
3M,Neotechnic | 2.76±0.01mm | 1.68±0.04mm |
在本发明的第二方面中,通道8是经由喷嘴孔9连接至漏斗形构造的喷嘴开口。
自说明书的叙述可明了,根据本发明的装置适合用于以单一剂量给药适当活性物质、或任何适当活性物质混合物或制剂。
医药上有效的活性物质、活性物质混合物或制剂(药物制剂)的实例包括所有可吸入化合物,例如欧洲专利第1003 478号中所揭示的可吸入性大分子。优选地,使用通过吸入服用而用于治疗呼吸疾病的活性物质、活性物质混合物或制剂。
下文所列出的化合物可以其单独或组合用于本发明装置中。在下文所提及的化合物中,W是药理活性物质且选自(例如)下列物质中:β模拟物(betamimetic)、抗胆碱能药、皮质类固醇、PDE4-抑制剂、LTD4-拮抗剂、EGFR-抑制剂、多巴胺激动剂、H1-抗组织胺剂、PAF-拮抗剂及PI3-激酶抑制剂。此外,W的双重或三重组合可经组合并且用于本发明装置中。W的组合可能是(例如):
-W表示β模拟物与抗胆碱能药物、皮质类固醇、PDE4-抑制剂、EGFR-抑制剂或LTD4-拮抗剂的组合,
-W表示抗胆碱能药物与β模拟物、皮质类固醇、PDE4-抑制剂、EGFR-抑制剂或LTD4-拮抗剂的组合,
-W表示皮质类固醇与PDE4-抑制剂、EGFR-抑制剂或LTD4-拮抗剂的组合,
-W表示PDE4-抑制剂与EGFR-抑制剂或LTD4-拮抗剂的组合,
-W表示EGFR-抑制剂与LTD4-拮抗剂的组合。
优选地,用作β模拟物的化合物是选自下列中的化合物:沙丁胺醇、阿福莫特罗(arformoterol)、班布特罗、比托特罗、溴沙特罗、卡布特罗、克仑特罗、非诺特罗、福莫特罗、海索那林、异丁特罗、乙基异丙肾上腺素、异丙肾上腺素、左沙丁胺醇、马布特罗、美卢君、间羟异丙肾上腺素、奥西那林、吡布特罗、丙卡特罗、瑞普特罗、利米特罗、利托君、沙甲胺醇、沙美特罗、索特瑞醇(soterenol)、索芬特罗(sulphonterol)、特布他林、噻拉米特、特鲁布特罗(tolubuterol)、净特罗(zinterol)、CHF-1035、HOKU-81、KUL-1248,
3-(4-{6-[2-羟基-2-(4-羟基-3-羟基甲基-苯基)-乙基氨基]-己基氧基}-丁基)-苄基-磺酰胺
5-[2-(5,6-二乙基-茚满-2-基氨基)-1-羟基-乙基]-8-羟基-1H-喹啉-2-酮
4-羟基-7-[2-{[2-{[3-(2-苯基乙氧基)丙基]磺酰基}乙基]-氨基}乙基]-2(3H)-苯并噻唑酮
1-(2-氟-4-羟基苯基)-2-[4-(1-苯并咪唑基)-2-甲基-2-丁基氨基]乙醇
1-[3-(4-甲氧基苄基-氨基)-4-羟基苯基]-2-[4-(1-苯并咪唑基)-2-甲基-2-丁基氨基]乙醇
1[2H-5-羟基-3-氧代-4H-1,4-苯并噁嗪-8-基]-2-[3-(4-N,N-二甲基氨基苯基)-2-甲基-2-丙基氨基]乙醇
1-[2H-5-羟基-3-氧代-4H-1,4-苯并噁嗪-8-基]-2-[3-(4-甲氧基苯基)-2-甲基-2-丙基氨基]乙醇
1-[2H-5-羟基-3-氧代-4H-1,4-苯并噁嗪-8-基]-2-[3-(4-正丁基氧基苯基)-2-甲基-2-丙基氨基]乙醇
1-[2H-5-羟基-3-氧代-4H-1,4-苯并噁嗪-8-基]-2-{4-[3-(4-甲氧基苯基)-1,2,4-三唑-3-基]-2-甲基-2-丁基氨基}乙醇
5-羟基-8-(1-羟基-2-异丙基氨基丁基)-2H-1,4-苯并噁嗪-3-(4H)-酮
1-(4-氨基-3-氯-5-三氟甲基苯基)-2-叔丁基氨基)乙醇
6-羟基-8-{1-羟基-2-[2-(4-甲氧基-苯基)-1,1-二甲基-乙基氨基]-乙基}-4H-苯并[1,4]噁嗪-酮
6-羟基-8-{1-羟基-2-[2-(4-苯氧基-乙酸乙基酯)-1,1-二甲基-乙基氨基]-乙基}-4H-苯并[1,4]噁嗪-3-酮
6-羟基-8-{1-羟基-2-[2-(4-苯氧基-乙酸)-1,1-二甲基-乙基氨基]-乙基}-4H-苯并[1,4]噁嗪-3-酮
8-{2-[1,1-二甲基-2-(2,4,6-三甲基苯基)-乙基氨基]-1-羟基-乙基}-6-羟基-4H-苯并[1,4]噁嗪-3-酮
6-羟基-8-{1-羟基-2-[2-(4-羟基-苯基)-1,1-二甲基-乙基氨基]-乙基}-4H-苯并[1,4]噁嗪-3-酮
6-羟基-8-{1-羟基-2-[2-(4-异丙基-苯基)-1,1-二甲基-乙基氨基]-乙基}-4H-苯并[1,4]噁嗪-3-酮
8-{2-[2-(4-乙基-苯基)-1,1-二甲基-乙基氨基]-1-羟基-乙基}-6-羟基-4H-苯并[1,4]噁嗪-3-酮
8-{2-[2-(4-乙氧基-苯基)-1,1-二甲基-乙基氨基]-1-羟基-乙基}-6-羟基-4H-苯并[1,4]噁嗪-3-酮
4-(4-{2-[2-羟基-2-(6-羟基-3-氧代-3,4-二氢-2H-苯并[1,4]噁嗪-8-基)-乙基氨基]-2-甲基-丙基}-苯氧基)-丁酸
8-{2-[2-(3,4-二氟-苯基)-1,1-二甲基-乙基氨基]-1-羟基-乙基}-6-羟基-4H-苯并[1,4]噁嗪-3-酮
1-(4-乙氧基-羰基氨基-3-氰基-5-氟苯基)-2-(叔丁基氨基)乙醇
2-羟基-5-(1-羟基-2-{2-[4-(2-羟基-2-苯基-乙基氨基)-苯基]-乙基氨基}-乙基)-苯甲醛
N-[2-羟基-5-(1-羟基-2-{2-[4-(2-羟基-2-苯基-乙基氨基)-苯基]-乙基氨基}-乙基)-苯基]-甲酰胺
8-羟基-5-(1-羟基-2-{2-[4-(6-甲氧基-联苯-3-基氨基)-苯基]-乙基氨基}-乙基)-1H-喹啉-2-酮
8-羟基-5-[1-羟基-2-(6-苯乙基氨基-己基氨基)-乙基]-1H-喹啉-2-酮
5-[2-(2-{4-[4-(2-氨基-2-甲基-丙氧基)-苯基氨基]-苯基}-乙基氨基)-1-羟基-乙基]-8-羟基-1H-喹啉-2-酮
[3-(4-{6-[2-羟基-2-(4-羟基-3-羟基甲基-苯基)-乙基氨基]-己基氧基}-丁基)-5-甲基-苯基]-脲
4-(2-{6-[2-(2,6-二氯-苄氧基)-乙氧基]-己基氨基}-1-羟基-乙基)-2-羟基甲基-苯酚
3-(4-{6-[2-羟基-2-(4-羟基-3-羟基甲基-苯基)-乙基氨基]-己基氧基}-丁基)-苯磺酰胺
3-(3-{7-[2-羟基-2-(4-羟基-3-羟基甲基-苯基)-乙基氨基]-庚基氧基}-丙基)-苯磺酰胺
4-(2-{6-[4-(3-环戊烷磺酰基-苯基)-丁氧基]-己基氨基}-1-羟基-乙基)-2-羟基甲基-苯酚
N-金刚烷-2-基-2-(3-{2-[2-羟基-2-(4-羟基-3-羟基甲基-苯基)-乙基氨基]-丙基}-苯基)-乙酰胺,
任选以其外消旋体、对映异构体或非对映体的形式、或任选以其药理学可接受的酸加成盐、溶剂化物或水合物形式。根据本发明,β模拟物的酸加成盐优选选自下列各盐:盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、磷酸盐、甲烷磺酸盐、硝酸盐、马来酸盐、乙酸盐、柠檬酸盐、富马酸盐、酒石酸盐、草酸盐、琥珀酸盐、苯甲酸盐及对甲苯磺酸盐。
可提及的优选抗胆碱能剂的实例包括:噻托铵(Tiotropium)盐,优选为溴化物盐;氧托铵(Oxitropium)盐,优选为溴化物盐;氟托铵(Flutropium)盐,优选为溴化物盐;异丙托铵(Ipratropium)盐,优选为溴化物盐;格隆铵(Glycopyrronium)盐,优选为溴化物盐;曲司铵(Trospium)盐,优选为氯化物盐,即托特罗定(Tolterodin)。上文所提及的盐中,药理活性部分为阳离子,可能的阴离子为氯离子、溴离子、碘离子、硫酸根、磷酸根、甲烷磺酸根、硝酸根、马来酸根、乙酸根、柠檬酸根、富马酸根、酒石酸根、草酸根、琥珀酸根、苯甲酸根或对甲苯磺酸根,同时氯离子、溴离子物、碘离子、硫酸根、甲烷磺酸根或对甲苯磺酸根优选抗衡离子。就所有盐而言,氯化物、溴化物、碘化物及甲烷磺酸盐尤其优选。
其他优选抗胆碱能药是选自式AC-1的盐之中,
其中X-指示具有一个负电荷的阴离子,优选一选自下列中的阴离子:氟离子、氯离子、溴离子、碘离子、硫酸根、磷酸根、甲烷磺酸根、硝酸根、马来酸根、乙酸根、柠檬酸根、富马酸根、酒石酸根、草酸根、琥珀酸根、苯甲酸根及对甲苯磺酸根,尤其优选为溴离子,这些盐可任选呈其外消旋异构体、对映异构体或水合物形式。尤其重要者是含有式AC-1-对映异构体的对映异构体的哪些医药组合
其中X-可具有上文所述含义。其他优选抗胆碱能药是选自式AC-2的盐
其中R指示甲基或乙基,且其中X-可具有上文所述含义。
在替代性的实施方案中,式AC-2化合物亦可以游离碱AC-2-碱的形式存在。
AC-2-碱
其他特定化合物是:
2,2-二苯基丙酸托品醇酯甲溴化物、
2,2-二苯基丙酸莨菪品酯甲溴化物、
2-氟-2,2-二苯基乙酸莨菪品酯甲溴化物、
2-氟-2,2-二苯基乙酸托品醇酯甲溴化物、
3,3′,4,4′-四氟二苯乙醇酸托品醇酯甲溴化物、
3,3′,4,4′-四氟二苯乙醇酸莨菪品酯甲溴化物、
4,4′-二氟二苯乙醇酸托品醇酯甲溴化物、
4,4′-二氟二苯乙醇酸莨菪品酯甲溴化物、
3,3′-二氟二苯乙醇酸托品醇酯甲溴化物、
3,3′-二氟二苯乙醇酸莨菪品酯甲溴化物、
9-羟基-芴-9-羧酸托品醇酯甲溴化物、
9-氟-芴-9-羧酸托品醇酯甲溴化物、
9-羟基-芴-9-羧酸莨菪品酯甲溴化物、
9-氟-芴-9-羧酸莨菪品酯甲溴化物、
9-甲基-芴-9-羧酸托品醇酯甲溴化物、
9-甲基-芴-9-羧酸莨菪品酯甲溴化物、
二苯乙醇酸环丙基莨菪碱酯甲溴化物、
2,2-二苯基丙酸环丙基莨菪碱酯甲溴化物、
9-羟基-呫吨-9-羧酸环丙基莨菪碱酯甲溴化物、
9-甲基-芴-9-羧酸环丙基莨菪碱酯甲溴化物、
9-甲基-呫吨-9-羧酸环丙基莨菪碱酯甲溴化物、
9-羟基-芴-9-羧酸环丙基莨菪碱酯甲溴化物、
4,4′-二氟二苯乙醇酸环丙基莨菪碱甲基酯甲溴化物、
9-羟基-呫吨-9-羧酸托品醇酯甲溴化物、
9-羟基-呫吨-9-羧酸莨菪品酯甲溴化物、
9-甲基-呫吨-9-羧酸托品醇酯甲溴化物、
9-甲基-呫吨-9-羧酸莨菪品酯甲溴化物、
9-乙基-呫吨-9-羧酸托品醇酯甲溴化物、
9-二氟甲基-呫吨-9-羧酸托品醇酯甲溴化物,
9-羟基甲基-呫吨-9-羧酸莨菪品酯甲溴化物。
在本发明的范围内上文所述化合物亦可作为盐使用,其中除甲溴化物以外,这些盐可使用甲基-X,其中X可具有上文中针对X-所给出的含义。
作为皮质类固醇,优选使用选自下列中的化合物:
倍氯米松、倍他米松、布地奈德、布替可特(Butixocort)、环索奈德、地夫可特(Deflazacort)、地塞米松、埃普瑞诺(Etiprednol)、氟尼缩松、氟替卡松、氯替泼诺(Loteprednol)、莫米松、泼尼松龙、泼尼松、罗氟奈德、曲安西龙、RPR-106541、NS-126、ST-26及
6,9-二氟-17-[(2-呋喃基羰基)氧基]-11-羟基-16-甲基-3-氧代-雄甾-1,4-二烯-17-硫代碳酸(S)-氟甲基酯
6,9-二氟-11-羟基-16-甲基-3-氧代-17-丙酰氧基-雄甾-1,4-二烯-17-硫代碳酸(S)-(2-氧代-四氢-呋喃-3S-基)酯
6α,9α-二氟-11β-羟基-16α-甲基-3-氧代-17α-(2,2,3,3-四甲基环丙基羰基)氧基-雄甾-1,4-二烯-17β-羧酸氰基甲基酯
其任选呈外消旋形式,作为对映异构体、非对映异构体,或作为药理学上可接受的盐、溶剂合物或水合物的形式。皮质类固醇包括可能存在的任何盐或者衍生物、水合物或者溶剂合物。优选盐及衍生物的实例为碱金属盐(例如钠盐或钾盐)、磺酸基苯甲酸盐、磷酸盐、异烟碱酸盐、乙酸盐、二氯乙酸盐、丙酸盐、磷酸二氢盐、棕榈酸盐、特戊酸盐或糠酸盐。
可使用的PDE4-抑制剂优选是选自下列物质之中的化合物:恩丙茶碱、茶碱、罗氟司特、艾瑞福(西洛司特)、托福司特(Tofimilast)、普马芬群、利瑞司特(Lirimilast)、阿罗茶碱、阿替若玛、D4418、Bay-198004、BY343、CP-325,366、D-4396(Sch-351591)、AWD-12-281(GW-842470)、NCS-613、CDP-840、D-4418、PD-168787、T-440、T-2585、V-11294A、C1-1018、CDC-801、CDC-3052、D-22888、YM-58997、Z-15370及
N-(3,5-二氯-1-氧代-吡啶-4-基)-4-二氟甲氧基-3-环丙基甲氧基苯甲酰胺、
(-)对-[(4aR*,10bS*)-9-乙氧基-1,2,3,4,4a,10b-六氢-8-甲氧基-2-甲基苯并[s][1,6]二氮杂萘-6-基]-N,N-二异丙基苯甲酰胺
(R)-(+)-1-(4-溴代苄基)-4-[(3-环戊基氧基)-4-甲氧基苯基]-2-吡咯烷酮
3-(环戊基氧基-4-甲氧基苯基)-1-(4-N′-[N-2-氰基-S-甲基-异硫脲基]苄基)-2-吡咯烷酮
顺[4-氰基-4-(3-环戊基氧基-4-甲氧基苯基)环己烷-1-羧酸]
2-甲酯基-4-氰基-4-(3-环丙基甲氧基-4-二氟甲氧基苯基)环己-1-酮
顺[4-氰基-4-(3-环丙基甲氧基-4-二氟甲氧基苯基)环己-1-醇]
(R)-(+)-乙基[4-(3-环戊基氧基-4-甲氧基苯基)吡咯烷-2-亚基]乙酸酯
(S)-(-)-乙基[4-(3-环戊基氧基-4-甲氧基苯基)吡咯烷-2-亚基]乙酸酯
9-环戊基-5,6-二氢-7-乙基-3-(2-噻吩基)-9H-吡唑并[3,4-c]-1,2,4-三唑并[4,3-a]吡啶
9-环戊基-5,6-二氢-7-乙基-3-(叔丁基)-9H-吡唑并[3,4-c]-1,2,4-三唑并[4,3-a]吡啶,
任选以其外消旋体、对映异构体或非对映体的形式,或者任选以其药理学可接受的酸加成盐、溶剂化物或水合物形式。根据本发明,PDE4-抑制剂的酸加成盐优选为选自由下列各盐:盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、磷酸盐、硝酸盐、马来酸盐、乙酸盐、柠檬酸盐、富马酸盐、酒石酸盐、草酸盐、琥珀酸盐、苯甲酸盐和对甲苯磺酸盐。
所使用的LTD4-拮抗剂优选是选自下列物质中的化合物:孟鲁司特、普仑司特、扎鲁司特、MCC-847(ZD-3523)、MN-001、MEN-91507(LM-1507)、VUF-5078、VUF-K-8707、L-733321及
1-(((R)-(3-(2-(6,7-二氟-2-喹啉基)乙烯基)苯基)-3-(2-(2-羟基-2-丙基)苯基)-硫基)-甲基-环丙烷-乙酸
1-(((1(R)-3(3-(2-(2,3-二氯噻吩并[3,2-b]吡啶-5-基)-(E)-乙烯基)苯基)-3-(2-(1-羟基-1-甲基-乙基)苯基)丙基)硫基)甲基)环丙烷-乙酸
[2-[[2-(4-叔丁基-2-噻唑基)-5-苯并呋喃基]氧基甲基]苯基]-乙酸
任选以其外消旋体、对映异构体或非对映体的形式,或任选以其药理学可接受的酸加成盐的形式、溶剂化物或水合物形式。根据本发明的酸加成盐优选为选自各盐:盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、磷酸盐、硝酸盐、马来酸盐、乙酸盐、柠檬酸盐、富马酸盐、酒石酸盐、草酸盐、琥珀酸盐、苯甲酸盐和对甲苯磺酸盐。LTD4-拮抗剂的盐或者衍生物可任选地形成碱金属盐(例如钠盐或钾盐)、磺酸基苯甲酸盐、磷酸盐、异烟碱酸盐、乙酸盐、丙酸盐、磷酸二氢盐、棕榈酸盐、特戊酸盐或糠酸盐。
可使用的EGFR-抑制剂优选地是选自下列物质中的化合物:西妥昔单抗、曲妥单抗、ABX-EGF、Mab ICR-62及
4-[(3-氯-4-氟苯基)氨基]-6-{[4-(吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-7-环丙基甲氧基-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N,N-二乙基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-环丙基甲氧基-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N,N-二5甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-环丙基甲氧基-喹唑啉
4-[(R)-(1-苯基-乙基)氨基]-6-{[4-(吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-7-环戊基氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{[4-((R)-6-甲基-2-氧代-吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-7-环丙基甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{[4-((R)-6-甲基-2-氧代-吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-7-[(S)-(四氢呋喃-3-基)氧基]-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{[4-((R)-2-甲氧基甲基-6-氧代-吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-7-环丙基甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-[2-((S)-6-甲基-2-氧代-吗啉-4-基)-乙氧基]-7-甲氧基-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-6-({4-[N-(2-甲氧基-乙基)-N-甲基-氨基]-1-氧代-2-丁烯-1-基}氨基)-7-环丙基甲氧基-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N,N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-环戊基氧基-喹唑啉
4-[(R)-(1-苯基-乙基)氨基]-6-{[4-(N,N-双-(2-甲氧基-乙基)-氨基)-1-氧代-2-丁烯-1-基]氨基}-7-环丙基甲氧基-喹唑啉
4-[(R)-(1-苯基-乙基)氨基]-6-({4-[N-(2-甲氧基-乙基)-N-乙基-氨基]-1-氧代-2-丁烯-1-基}氨基)-7-环丙基甲氧基-喹唑啉
4-[(R)-(1-苯基-乙基)氨基]-6-({4-[N-(2-甲氧基-乙基)-N-甲基-氨基]-1-氧代-2-丁烯-1-基}氨基)-7-环丙基甲氧基-喹唑啉
4-[(R)-(1-苯基-乙基)氨基]-6-({4-[N-(四氢吡喃-4-基)-N-甲基-氨基]-1-氧代-2-丁烯-1-基}氨基)-7-环丙基甲氧基-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N,N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-((R)-四氢呋喃-3-基氧基)-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N,N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-((S)-四氢呋喃-3-基氧基)-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-6-{[4-[N-(2-甲氧基-乙基)-N-甲基-氨基]-1-氧代-2-丁烯-1-基}氨基)-7-环戊基氧基-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N-环丙基-N-甲基-氨基)-1-氧代-2-丁烯-1-基]氨基}-7-环戊基氧基-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N,N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-[(R)-(四氢呋喃-2-基)甲氧基)-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N,N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-[(S)-(四氢呋喃-2-基)甲氧基)-喹唑啉
4-[(3-乙炔基-苯基)氨基]-6,7-双-(2-甲氧基-乙氧基)-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-7-[3-(吗啉-4-基)-丙基氧基]-6-[(乙烯基-羰基)氨基]-喹唑啉
4-[(R)-(1-苯基-乙基)氨基]-6-(4-羟基-苯基)-7H-吡咯并[2,3-d]嘧啶
3-氰基-4-[(3-氯-4-氟苯基)氨基]-6-{[4-(N,N-二甲基氨基)-1-氧代-2-丁烯-1-基]氨基}-7-乙氧基-喹啉
4-{[3-氯-4-(3-氟-苄氧基)-苯基]氨基}-6-(5-{[(2-甲烷磺酰基-乙基)氨基]甲基}-呋喃-2-基)喹唑啉
4-[(R)-(1-苯基-乙基)氨基]-6-{[4-((R)-6-甲基-2-氧代-吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-6-{[4-(吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-7-[(四氢呋喃-2-基)甲氧基]-喹唑啉
4-[(3-氯-4-氟苯基)氨基]-6-({4-[N,N-双-(2-甲氧基-乙基)-氨基]-1-氧代-2-丁烯-1-基}氨基)-7-[(四氢呋喃-2-基)甲氧基]-喹唑啉
4-[(3-乙炔基-苯基)氨基]-6-{[4-(5,5-二甲基-2-氧代-吗啉-4-基)-1-氧代-2-丁烯-1-基]氨基}-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-[2-(2,2-二甲基-6-氧代-吗啉-4-基)-乙氧基]-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-[2-(2,2-二甲基-6-氧代-吗啉-4-基)-乙氧基]-7-[(R)-(四氢呋喃-2-基)甲氧基]-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-7-[2-(2,2-二甲基-6-氧代-吗啉-4-基)-乙氧基]-6-[(S)-(四氢呋喃-2-基)甲氧基]-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{2-[4-(2-氧代-吗啉-4-基)-哌啶-1-基]-乙氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-[1-(叔丁基氧基羰基)-哌啶-4-基氧基]-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(反-4-氨基-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(反-4-甲烷磺酰基氨基-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(四氢吡喃-3-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(1-甲基-哌啶-4-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(吗啉-4-基)羰基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(甲氧基甲基)羰基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(哌啶-3-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-[1-(2-乙酰基氨基-乙基)-哌啶-4-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(四氢吡喃-4-基氧基)-7-乙氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-((S)-四氢呋喃-3-基氧基)-7-羟基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(四氢吡喃-4-基氧基)-7-(2-甲氧基-乙氧基)-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{反-4-[(二甲基氨基)磺酰基氨基]-环己-1-基氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{反-4-[(吗啉-4-基)羰基氨基]-环己-1-基氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{反-4-[(吗啉-4-基)磺酰基氨基]-环己-1-基氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(四氢吡喃-4-基氧基)-7-(2-乙酰基氨基-乙氧基)-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(四氢吡喃-4-基氧基)-7-(2-甲烷磺酰基氨基-乙氧基)-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(哌啶-1-基)羰基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(1-氨基羰基甲基-哌啶-4-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(顺-4-{N-[(四氢吡喃-4-基)羰基]-N-甲基-氨基}-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(顺-4-{N-[(吗啉-4-基)羰基]-N-甲基-氨基}-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(顺-4-{N-[(吗啉-4-基)磺酰基]-N-甲基-氨基}-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(反-4-乙烷磺酰基氨基-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(1-甲烷磺酰基-哌啶-4-基氧基)-7-乙氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(1-甲烷磺酰基-哌啶-4-基氧基)-7-(2-甲氧基-乙氧基)-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-[1-(2-甲氧基-乙酰基)-哌啶-4-基氧基]-7-(2-甲氧基-乙氧基)-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(顺-4-乙酰基氨基-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-乙炔基-苯基)氨基]-6-[1-(叔丁基氧基羰基)-哌啶-4-基氧基]-7-甲氧基-喹唑啉
4-[(3-乙炔基-苯基)氨基]-6-(四氢吡喃-4-基氧基]-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(顺-4-{N-[(哌啶-1-基)羰基]-N-甲基-氨基}-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(顺-4-{N-[(4-甲基-哌嗪-1-基)羰基]-N-甲基-氨基}-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{顺-4-[(吗啉-4-基)羰基氨基]-环己-1-基氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{1-[2-(2-氧代吡咯烷-1-基)乙基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(吗啉-4-基)羰基]-哌啶-4-基氧基}-7-(2-甲氧基-乙氧基)-喹唑啉
4-[(3-乙炔基-苯基)氨基]-6-(1-乙酰基-哌啶-4-基氧基)-7-甲氧基-喹唑啉
4-[(3-乙炔基-苯基)氨基]-6-(1-甲基-哌啶-4-基氧基)-7-甲氧基-喹唑啉
4-[(3-乙炔基-苯基)氨基]-6-(1-甲烷磺酰基-哌啶-4-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(1-甲基-哌啶-4-基氧基)-7-(2-甲氧基-乙氧基)喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(1-异丙基氧基羰基-哌啶-4-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(顺-4-甲基氨基-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{顺-4-[N-(2-甲氧基-乙酰基)-N-甲基-氨基]-环己-1-基氧基}-7-甲氧基-喹唑啉
4-[(3-乙炔基-苯基)氨基]-6-(哌啶-4-基氧基)-7-甲氧基-喹唑啉
4-[(3-乙炔基-苯基)氨基]-6-[1-(2-甲氧基-乙酰基)-哌啶-4-基氧基]-7-甲氧基-喹唑啉
4-[(3-乙炔基-苯基)氨基]-6-{1-[(吗啉-4-基)羰基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(顺-2,6-二甲基-吗啉-4-基)羰基]-哌啶-4-基氧基]-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(2-甲基-吗啉-4-基)羰基]-哌啶-4-基氧基]-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(S,S)-(2-氧杂-5-氮杂-双环[2.2.1]庚-5-基)羰基]-哌啶-4-基氧基]-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(N-甲基-N-2-甲氧基乙基-氨基)羰基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(1-乙基-哌啶-4-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(2-甲氧基乙基)羰基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-{1-[(3-甲氧基丙基-氨基)羰基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-[顺-4-(N-甲烷磺酰基-N-甲基-氨基)-环己-1-基氧基]-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-[顺-4-(N-乙酰基-N-甲基-氨基)-环己-1-基氧基]-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(反-4-甲基氨基-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-[反-4-(N-甲烷磺酰基-N-甲基-氨基)-环己-1-基氧基]-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(反-4-二甲基氨基-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(反-4-{N-[(吗啉-4-基)羰基]-N-甲基-氨基}-环己-1-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-[2-(2,2-二甲基-6-氧代-吗啉-4-基)-乙氧基]-7-[(S)-(四氢呋喃-2-基)甲氧基]-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(1-甲烷磺酰基-哌啶-4-基氧基)-7-甲氧基-喹唑啉
4-[(3-氯-4-氟-苯基)氨基]-6-(1-氰基-哌啶-4-基氧基)-7-甲氧基-喹唑啉,
任选以其外消旋体、对映异构体或非对映体的形式且任选以其药理学可接受的酸加成盐、溶剂化物或水合物形式。根据本发明,这些酸加成盐优选地选自下列各盐:盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、磷酸盐、硝酸盐、马来酸盐、乙酸盐、柠檬酸盐、富马酸盐、酒石酸盐、草酸盐、琥珀酸盐、苯甲酸盐和对甲苯磺酸盐。
所使用的多巴胺激动剂优选地是选自下列物质中的化合物:溴隐亭、卡麦角林、α-二氢麦角卡里碱(α-Dihydroergocryptine)、麦角乙脲、培高利特、普拉克索、罗克吲哚、罗匹尼罗、他利克索、特麦角脲及维赞(Viozane),其任选呈外消旋形式,为对映异构体、非对映异构体,或为药理学上可接受的盐、溶剂合物或水合物。根据本发明,这些酸加成盐优选为选自下列各盐:盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、磷酸盐、甲烷磺酸盐、硝酸盐、马来酸盐、乙酸盐、柠檬酸盐、富马酸盐、酒石酸盐、草酸盐、琥珀酸盐、苯甲酸盐及对甲苯磺酸盐。
可使用的H1-抗组织胺剂优选地是选自下列物质中的化合物:依匹斯汀、西替利嗪、氮卓斯汀、非索非那定、左卡巴斯汀、氯雷他定、咪唑斯汀、可多替芬(Ketotifen)、依美斯汀、二甲茚定、氯马斯汀、巴米品、右旋氯苯那敏(Cexchlorpheniramine)、非尼拉敏、多西拉敏、氯苯沙明、茶苯海明、苯海拉明、异丙嗪、依巴斯汀、地氯雷地定(Desloratidine)及美克洛嗪,其任选呈外消旋形式,作为对映异构体、非对映异构体,或为药理学上可接受的盐、溶剂合物或水合物。根据本发明,这些酸加成盐优选为选自由下列各盐:盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、磷酸盐、硝酸盐、马来酸盐、乙酸盐、柠檬酸盐、富马酸盐、酒石酸盐、草酸盐、琥珀酸盐、苯甲酸盐和对甲苯磺酸盐。
亦可使用如欧洲专利第1 003 478号中所揭示的可吸入大分子。
此外,所述的化合物可选自下列各物质的衍生物:麦角生物碱的衍生物、曲坦类(triptane)、CGRP-拮抗剂、磷酸二酯酶-V-抑制剂,其任选呈外消旋体、对映异构体、非对映异构体形式,及任选其药理学上可接受的酸加成盐、溶剂合物及/或水合物。
麦角生物碱衍生物的实例是二氢麦角胺及麦角胺。
为了吸入,适合的物质包括具有上文所述活性物质、以及其盐及酯及这些活性物质、盐及酯的组合的药物组合物、药物制剂及混合物。
该药物制剂可另外地含有标准市售悬浮液辅助剂、表面活性剂及/或稳定剂。
Claims (9)
1.一种用于提供药用活性物质、活性物质混合物及制剂的装置,该装置包括充填了药物制剂的容器及阀门,该药物制剂是包含存于经加压液化的1.1.1.2-四氟乙烷(HFC-134a)或1.1.1.2.3.3.3-七氟丙烷(HFC-227)或HFC-134a及HFC-227的混合物中的活性物质、活性物质混合物或制剂,该阀门是经配置以将药物制剂的单剂量递送出该装置,该装置的特征在于该装置的吸嘴管具有没有或几乎没有死区的通道(8)。
2.如权利要求1所述的装置,其特征在于该药物制剂另外含有悬浮液辅助剂、表面活性剂及/或稳定剂。
3.如权利要求1或2所述的装置,其特征在于该通道(8)经由喷嘴孔(9)连接至具有漏斗形构造的喷嘴开口(10)。
4.如权利要求1至3之一所述的装置,其特征在于该喷嘴孔(9)具有0.2-0.6mm的直径。
5.如权利要求1至4之一所述的装置,其是用于提供药物制剂,该药物制剂含有抗胆碱能药、β模拟物、类固醇、磷酸二酯酶-IV-抑制剂、LTD4-拮抗剂及EGFR-激酶抑制剂、抗过敏剂、麦角生物碱衍生物、曲坦类药物、CGRP-拮抗剂、磷酸二酯酶-V-抑制剂及这些活性物质的组合。
6.如权利要求1至5之一所述的装置,其特征在于该喷嘴开口是根据图3或4来构造的。
7.一种吸嘴管,其是由竖筒(2)、阀杆插座(5)、喷嘴孔(9)及吸嘴(6)所构成,该吸嘴管这样容纳计量剂量喷雾剂,即,使该吸嘴管的竖筒(2)环绕计量剂量喷雾剂(1),该吸嘴管的阀杆插座(5)密封地环绕该计量阀门(3)的阀杆(4),并且,其具有通道(8),其中,该实际喷嘴孔(9)相对于该通道(8)的垂直轴线呈钝夹角地通向该通道(8),因此,在压力下液化的医药组合物、混合物或制剂是自该阀杆(7)的垂直向下配置的开口偏转>90°且经由该喷嘴孔(9)通向外部,藉此在自该喷嘴孔(9)至该喷嘴开口(10)的过渡处产生喷雾云,其特征在于该通道(8)没有或几乎没有死区。
8.如权利要求7所述的吸嘴管,其特征在于该通道(8)是经由喷嘴孔(9)连接至具有漏斗形构造的喷嘴开口(10)。
9.如权利要求7或8所述的吸嘴管,其特征在于该喷嘴孔(9)具有0.2-0.6mm的直径。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006014433.3 | 2006-03-27 | ||
DE102006014433A DE102006014433A1 (de) | 2006-03-27 | 2006-03-27 | Dosieraerosole für die Verabreichung von pharmazeutischen Zubereitungen |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101410189A true CN101410189A (zh) | 2009-04-15 |
Family
ID=38176097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA200780011089XA Pending CN101410189A (zh) | 2006-03-27 | 2007-03-26 | 用以施用药物制剂的剂量喷雾器 |
Country Status (19)
Country | Link |
---|---|
US (2) | US20070221213A1 (zh) |
EP (1) | EP2001601B1 (zh) |
JP (1) | JP4903857B2 (zh) |
KR (1) | KR20080108141A (zh) |
CN (1) | CN101410189A (zh) |
AR (1) | AR060072A1 (zh) |
AU (1) | AU2007229531A1 (zh) |
BR (1) | BRPI0709198A2 (zh) |
CA (1) | CA2646612A1 (zh) |
DE (1) | DE102006014433A1 (zh) |
EA (1) | EA200801889A1 (zh) |
EC (1) | ECSP088732A (zh) |
MX (1) | MX2008011702A (zh) |
NO (1) | NO20083759L (zh) |
PE (1) | PE20071300A1 (zh) |
TW (1) | TW200815059A (zh) |
UY (1) | UY30241A1 (zh) |
WO (1) | WO2007110403A1 (zh) |
ZA (1) | ZA200807348B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102686261A (zh) * | 2009-12-23 | 2012-09-19 | Map药物公司 | 增强型的喷射器设计 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004011381A1 (de) | 2004-03-05 | 2005-09-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Impaktionsdüse für treibgasbetriebene Dosieraerosole |
DE102006014433A1 (de) | 2006-03-27 | 2007-10-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dosieraerosole für die Verabreichung von pharmazeutischen Zubereitungen |
EP2011534A1 (en) * | 2007-07-03 | 2009-01-07 | CHIESI FARMACEUTICI S.p.A. | Metered dose inhaler actuator |
CA2730419A1 (en) * | 2008-07-11 | 2010-01-14 | Map Pharmaceuticals, Inc. | Containers for aerosol drug delivery |
NZ600208A (en) * | 2009-11-17 | 2014-06-27 | Cipla Ltd | Inhalation solutions |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE639762A (zh) * | 1962-11-16 | |||
US3236457A (en) * | 1963-08-21 | 1966-02-22 | John R Kennedy | Composite spray container assembly |
US3367330A (en) * | 1965-07-06 | 1968-02-06 | Stanis A. Sierpin | Aerosol type dispenser for fluids |
US3383879A (en) * | 1966-04-04 | 1968-05-21 | Chill Master Corp | Glass chiller |
AT304349B (de) * | 1970-06-19 | 1972-12-27 | Ciba Geigy Ag | Betätigungskopf für einen Aerosolzerstäuber |
US3920158A (en) * | 1973-11-27 | 1975-11-18 | Philip Meshberg | Dual Dispensing valve |
US4217360A (en) * | 1975-02-27 | 1980-08-12 | Schering Aktiengesellschaft | Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof |
US3994421A (en) | 1975-09-29 | 1976-11-30 | American Cyanamid Company | Unitary therapeutic aerosol dispenser |
US4103684A (en) * | 1976-12-30 | 1978-08-01 | Aaron Ismach | Hydraulically powered hypodermic injector with adapters for reducing and increasing fluid injection force |
DE2849590C2 (de) * | 1978-11-15 | 1981-11-19 | Schwarzkopf, Hans, 2000 Hamburg | In einem Behälter unter Druck stehendes Aerosolpräparat, Verfahren zu seiner Herstellung und Verwendung der Aerosolpräparate unter Druck in einem Behälter (Aerosoldose) |
CH652468A5 (de) * | 1980-08-06 | 1985-11-15 | Werding Winfried J | Schubregler zur verwendung im innern eines unter gasdruck stehenden behaelters. |
GB8311167D0 (en) * | 1983-04-25 | 1983-06-02 | Jenkins W N | Directed spray |
EP0261649B2 (en) * | 1986-09-22 | 1995-04-26 | Omron Tateisi Electronics Co. | Nebulizer |
US4801465A (en) * | 1987-04-20 | 1989-01-31 | Sponer Richard A | Dispenser apparatus for a solid particulate material and a fluid |
GB8917775D0 (en) * | 1989-08-03 | 1989-09-20 | Atomic Energy Authority Uk | Aerosol inhaler |
US5249747A (en) * | 1990-07-12 | 1993-10-05 | Par-Way Group | Sprayable dispensing system for viscous vegetable oils and apparatus therefor |
DE4102506C2 (de) * | 1991-01-29 | 1999-11-25 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
US5190029A (en) * | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
US5524798A (en) * | 1992-02-24 | 1996-06-11 | Djs&T Limited Partnership | Spray texturing nozzles having variable orifice |
IL107120A (en) * | 1992-09-29 | 1997-09-30 | Boehringer Ingelheim Int | Atomising nozzle and filter and spray generating device |
US5899201A (en) * | 1993-05-26 | 1999-05-04 | Minnesota Mining And Manufacturing Company | Aerosol actuator |
US5358179A (en) * | 1993-08-18 | 1994-10-25 | The Procter & Gamble Company | Atomization systems for high viscosity products |
US5505192A (en) * | 1993-11-12 | 1996-04-09 | New-Med Corporation | Dispenser monitoring system |
US5634571A (en) * | 1995-06-07 | 1997-06-03 | Innavision Services, Inc. | Apparatus for dispensing two sprayable substances in a user selectable ratio |
US6357442B1 (en) * | 1995-06-08 | 2002-03-19 | Innovative Devices, Llc | Inhalation actuated device for use with metered dose inhalers (MDIS) |
GB9706121D0 (en) | 1997-03-25 | 1997-05-14 | Bespak Plc | Inhalation device |
US5904139A (en) * | 1997-03-28 | 1999-05-18 | Hauser; Stephen G. | Breath coordinated inhaler |
GB2324121A (en) | 1997-04-07 | 1998-10-14 | Bespak Plc | Seal arrangements for pressurised dispensing containers |
DE19733651A1 (de) | 1997-08-04 | 1999-02-18 | Boehringer Ingelheim Pharma | Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole |
US20060239930A1 (en) * | 1997-08-04 | 2006-10-26 | Herbert Lamche | Process for nebulizing aqueous compositions containing highly concentrated insulin |
GB9807232D0 (en) * | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
CA2329900A1 (en) * | 1998-04-30 | 1999-11-04 | 3M Innovative Properties Company | Metered-dose valve for pharmaceutical aerosol |
AU5970899A (en) * | 1998-08-28 | 2000-03-21 | Glaxo Group Limited | Dispenser |
GB2345010B (en) * | 1998-12-17 | 2002-12-31 | Electrosols Ltd | A delivery device |
FR2791956B1 (fr) * | 1999-04-12 | 2001-06-01 | Oreal | Tete de distribution pour dispositif du type a valve ou a pompe |
FR2796925B1 (fr) * | 1999-07-29 | 2001-10-05 | Valois Sa | Distributeur a tete de distribution articulee |
CO5270018A1 (es) * | 1999-12-11 | 2003-04-30 | Glaxo Group Ltd | Distribuidor de medicamento |
GB0026647D0 (en) | 2000-10-31 | 2000-12-13 | Glaxo Group Ltd | Medicament dispenser |
JP2004522514A (ja) * | 2001-01-25 | 2004-07-29 | クリニカル・デザインズ・リミテッド | 薬剤の投与装置 |
EP1321159A1 (en) * | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices |
GB0217198D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
AU2003276450A1 (en) * | 2002-11-04 | 2004-06-07 | Cambridge Consultants Limited | Pressurised inhalers |
CN1761455A (zh) | 2003-03-20 | 2006-04-19 | 贝林格尔·英格海姆药物公司 | 采用氢-氟-烷作为推进剂的计量剂量吸入器制剂 |
GB0322284D0 (en) * | 2003-09-23 | 2003-10-22 | Glaxo Group Ltd | Medicament dispenser |
CA2540179A1 (en) * | 2003-09-24 | 2005-03-31 | Medi-Stream Pty Ltd | Medication holder |
GB0328502D0 (en) * | 2003-12-10 | 2004-01-14 | 3M Innovative Properties Co | Metered dose dispensers and assemblies therefor |
DE102004011381A1 (de) * | 2004-03-05 | 2005-09-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Impaktionsdüse für treibgasbetriebene Dosieraerosole |
GB2417480B (en) * | 2004-12-15 | 2006-08-02 | Bespak Plc | Improvements in or relating to valves |
CA2590839A1 (en) * | 2004-12-15 | 2006-06-22 | 3M Innovative Properties Company | Elastomer seals for use in medicinal aerosol devices |
DE102006014433A1 (de) | 2006-03-27 | 2007-10-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dosieraerosole für die Verabreichung von pharmazeutischen Zubereitungen |
-
2006
- 2006-03-27 DE DE102006014433A patent/DE102006014433A1/de not_active Withdrawn
-
2007
- 2007-03-23 AR ARP070101191A patent/AR060072A1/es unknown
- 2007-03-23 PE PE2007000319A patent/PE20071300A1/es not_active Application Discontinuation
- 2007-03-26 UY UY30241A patent/UY30241A1/es not_active Application Discontinuation
- 2007-03-26 WO PCT/EP2007/052857 patent/WO2007110403A1/de active Application Filing
- 2007-03-26 JP JP2009502056A patent/JP4903857B2/ja active Active
- 2007-03-26 AU AU2007229531A patent/AU2007229531A1/en not_active Abandoned
- 2007-03-26 MX MX2008011702A patent/MX2008011702A/es not_active Application Discontinuation
- 2007-03-26 CA CA002646612A patent/CA2646612A1/en not_active Abandoned
- 2007-03-26 TW TW096110390A patent/TW200815059A/zh unknown
- 2007-03-26 EP EP07727330.8A patent/EP2001601B1/de active Active
- 2007-03-26 EA EA200801889A patent/EA200801889A1/ru unknown
- 2007-03-26 CN CNA200780011089XA patent/CN101410189A/zh active Pending
- 2007-03-26 KR KR1020087026138A patent/KR20080108141A/ko not_active Application Discontinuation
- 2007-03-26 BR BRPI0709198-2A patent/BRPI0709198A2/pt not_active Application Discontinuation
- 2007-03-27 US US11/691,890 patent/US20070221213A1/en not_active Abandoned
-
2008
- 2008-08-26 ZA ZA200807348A patent/ZA200807348B/xx unknown
- 2008-09-01 NO NO20083759A patent/NO20083759L/no not_active Application Discontinuation
- 2008-09-10 EC EC2008008732A patent/ECSP088732A/es unknown
-
2011
- 2011-02-03 US US13/020,200 patent/US9937306B2/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102686261A (zh) * | 2009-12-23 | 2012-09-19 | Map药物公司 | 增强型的喷射器设计 |
CN102686261B (zh) * | 2009-12-23 | 2014-09-10 | Map药物公司 | 增强型的喷射器设计 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0709198A2 (pt) | 2011-06-28 |
CA2646612A1 (en) | 2007-10-04 |
WO2007110403A1 (de) | 2007-10-04 |
AU2007229531A1 (en) | 2007-10-04 |
KR20080108141A (ko) | 2008-12-11 |
EP2001601A1 (de) | 2008-12-17 |
UY30241A1 (es) | 2007-10-31 |
US20110186044A1 (en) | 2011-08-04 |
JP4903857B2 (ja) | 2012-03-28 |
US20070221213A1 (en) | 2007-09-27 |
JP2009531102A (ja) | 2009-09-03 |
NO20083759L (no) | 2008-10-21 |
US9937306B2 (en) | 2018-04-10 |
ZA200807348B (en) | 2009-08-26 |
ECSP088732A (es) | 2008-10-31 |
DE102006014433A1 (de) | 2007-10-04 |
PE20071300A1 (es) | 2008-02-04 |
EA200801889A1 (ru) | 2009-04-28 |
EP2001601B1 (de) | 2014-05-14 |
AR060072A1 (es) | 2008-05-21 |
TW200815059A (en) | 2008-04-01 |
MX2008011702A (es) | 2008-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104799969B (zh) | 吸入器 | |
CN101300041B (zh) | 计量药物的方法与装置 | |
CN101918144B (zh) | 喷嘴、吸入器以及生产喷嘴的方法 | |
CN101309715A (zh) | 用于穿刺吸入粉末胶囊的针 | |
CN101340981A (zh) | 施配装置 | |
CN101754780B (zh) | 粉末吸入器 | |
CN108495680A (zh) | 由上锁功能和计数器组成的吸入喷雾器 | |
TW200800294A (en) | Pharmaceutical composition for aerosols with two or more active substances and at least one surfactant | |
CN101484200A (zh) | 吸入器 | |
RU2470680C2 (ru) | Ингалятор | |
TW201004663A (en) | Inhaler | |
CN101977693A (zh) | 储器和喷雾器 | |
TW200808390A (en) | Inhaler | |
MXPA06015204A (es) | Formulaciones en suspension de aerosol con tg 227 ea o tg 134 a como agentes propulsores. | |
CN102573972A (zh) | 粉末吸入器 | |
JP2009533379A (ja) | 噴射剤としてTG227ea又はTG134aを含むエアロゾル懸濁液製剤 | |
CN101795721B (zh) | 吸入器 | |
JP2009537587A (ja) | エタノールを含んだ吸入エアロゾル製剤 | |
CN101410189A (zh) | 用以施用药物制剂的剂量喷雾器 | |
US20070041911A1 (en) | Hfc solution formulations containing salbutamol hydrochloride or salbutamol citrate | |
JP2012509922A (ja) | 新規粉末化結晶質吸入薬 | |
CN101384248A (zh) | 用于具有二种或多种活性剂以及至少一种表面活性剂的气雾剂的药物制剂 | |
CN101410147A (zh) | 具有最佳化排空性质的用于多剂量粉末吸入器的包装 | |
CA2626298A1 (en) | Propellant for dosing aerosols comprising packagings | |
CN1984642A (zh) | 包含TG227ea或TG134a作为推进剂的气溶胶悬浮制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1128651 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090415 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1128651 Country of ref document: HK |